Inactive Instrument

Other languages Heron Therapeutics Inc OTC Bulletin Board

Equities

APPAD

US4277461020

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Heron Therapeutics Says Non-Opioid Pain Medication to be Included in Proposed Medicare Programs	15/07
Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System	15/07
Heron Reports Acceptance of Prior Approval Supplement Application for Zynrelef Vial Access Needle	02/07
Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle	02/07
Connect Biopharma Names New Chief Executive, Chair	13/06
Heron Therapeutics Submits Prior Approval Supplement to the FDA for Zynrelef Vial Access Needle	29/05
Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")	29/05
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	07/05
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	22/03
Sector Update: Health Care Stocks Slipping Late Afternoon	14/03
Heron Therapeutics Shares Soar After Q4 Results Beat	13/03
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	13/03
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	24/01
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	24/01
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding	08/01
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket	08/01
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF	08/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Heron Therapeutics Inc OTC Bulletin Board

Equities

APPAD

US4277461020

Other languages

Filters